BidaskClub cut shares of Mast Therapeutics (NASDAQ:SVRA) from a strong-buy rating to a buy rating in a research report report published on Tuesday.

A number of other equities research analysts also recently issued reports on SVRA. JMP Securities initiated coverage on Mast Therapeutics in a research report on Monday, September 11th. They set an outperform rating and a $20.00 price target on the stock. Zacks Investment Research downgraded Mast Therapeutics from a buy rating to a hold rating in a research report on Friday, September 15th. Jefferies Group initiated coverage on Mast Therapeutics in a research report on Friday, September 22nd. They set a buy rating and a $20.00 price target on the stock. Roth Capital reissued a buy rating and set a $40.00 price target on shares of Mast Therapeutics in a research report on Wednesday, September 27th. Finally, Canaccord Genuity increased their price target on Mast Therapeutics from $18.00 to $25.00 and gave the stock a buy rating in a research report on Monday, October 30th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Mast Therapeutics has a consensus rating of Buy and an average price target of $23.58.

Shares of Mast Therapeutics (NASDAQ SVRA) opened at $13.05 on Tuesday. The stock has a market capitalization of $398.03, a P/E ratio of -3.88 and a beta of 0.18. Mast Therapeutics has a 12-month low of $4.60 and a 12-month high of $17.19. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.15 and a current ratio of 9.15.

In other Mast Therapeutics news, Director Yuri Pikover bought 50,000 shares of Mast Therapeutics stock in a transaction on Friday, October 27th. The shares were purchased at an average price of $7.85 per share, with a total value of $392,500.00. Following the acquisition, the director now owns 150,000 shares in the company, valued at approximately $1,177,500. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 6.93% of the company’s stock.

WARNING: “Mast Therapeutics (SVRA) Rating Lowered to Buy at BidaskClub” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at

About Mast Therapeutics

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Analyst Recommendations for Mast Therapeutics (NASDAQ:SVRA)

Receive News & Ratings for Mast Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.